Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A classification system for cross-reactive material-negative factor XI deficiency.

Dmitri V Kravtsov1, Paul E Monahan, David Gailani

  • 1Department of Pathology, Vanderbilt University, Nashville, TN 37232-6307, USA.

Blood
|February 25, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Novel C-Terminal Cystine Knot (Exon 52) VWF p.Cys2771Phe Variant Produces a Type 2A von Willebrand Factor Multimer Pattern with an Apparent Dimerization Defect.

Seminars in thrombosis and hemostasis·2026
Same author

Pharmacologic Factor XI/XIa Inhibitors: What the Laboratory Hematologist Needs to Know.

Clinics in laboratory medicine·2026
Same author

Bradykinin Contributes to Vasogenic Edema in Murine Experimental Cerebral Malaria.

bioRxiv : the preprint server for biology·2026
Same author

Reply to a letter from Miesbach and Srivastava: response to hemophilia B gene therapy based on adeno-associated virus serotype 5 antibody status.

Research and practice in thrombosis and haemostasis·2026
Same author

Reusing Blood Samples from a Hospital-based Cohort to Apixaban Plasma Concentrations.

medRxiv : the preprint server for health sciences·2026
Same author

Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trial.

Research and practice in thrombosis and haemostasis·2026
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Factor XI (FXI) deficiency can cause bleeding disorders. Novel mutations show FXI can negatively impact normal FXI secretion, explaining dominant inheritance patterns in some patients.

Area of Science:

  • Hematology
  • Molecular Biology
  • Genetics

Background:

  • Factor XI (FXI) deficiency typically presents as an autosomal recessive bleeding disorder.
  • However, certain FXI mutations can lead to dominant disease transmission.
  • FXI functions as a homodimer, a structural characteristic that may facilitate dominant-negative effects.

Observation:

  • Two novel FXI mutations, Ser225Phe and Cys398Tyr, were identified.
  • These mutations result in intracellular dimer formation and impaired secretion of FXI.
  • Cotransfection experiments demonstrated a dominant-negative effect on wild-type FXI secretion.

Findings:

  • Mutations causing cross-reactive material-negative FXI deficiency can be categorized into three mechanisms.
  • These include reduced polypeptide synthesis, failure to form dimers (monomer retention), or formation of non-secreted dimers.

Related Experiment Videos

  • The formation of non-secreted dimers is proposed as a key mechanism for dominant disease transmission.

    • Implications:

    • Understanding these mechanisms clarifies the molecular basis of FXI deficiency inheritance.
    • This knowledge aids in diagnosing and potentially treating bleeding disorders related to FXI.
    • The findings highlight the importance of protein dimerization in FXI function and disease pathology.